title: Treatment of advanced renal cell cancer with recombinant interferon alpha as a single agent and in combination with medroxyprogesterone acetate. A randomized multicenter trial.
abstract: The response rates in metastatic renal cell cancer (RCC) after chemotherapy, hormonal treatment, or immunotherapy rarely exceed 15%. Recently, interferon alpha (IFN alpha) was used for treatment of this disease in several studies which also demonstrated response rates of 15%. In order to test whether IFN therapy combined with hormones would result in higher response rates we compared single agent IFN therapy with a combined therapy of rIFN alpha 2C plus medroxyprogesterone acetate (MPA) in a randomized multicenter trial. The rIFN alpha 2C (2MU) was given s.c. 5 times per week for 8-12 weeks and subsequently once weekly until week 48. In the combined treatment, 750 mg MPA was given p.o. daily until week 48 in addition to the IFN as described. The overall response rate in 93 evaluable patients was 5.4% corresponding to 2 complete and 3 partial responses. Median survival was 7 months in both treatment groups. These data confirm the ineffectivity of low IFN doses for treatment of RCC. The low response rate is not increased by addition of MPA to IFN. The analysis of other IFN studies suggests that not only IFN doses but also IFN sources may influence response rates in metastatic RCC.
authors.affiliation: Tumor Zentrum Universität Ulm, FRG.
authors.forename: F
authors.initials: F
authors.lastname: Porzsolt
authors.forename: D
authors.initials: D
authors.lastname: Messerer
authors.forename: R
authors.initials: R
authors.lastname: Hautmann
authors.forename: A
authors.initials: A
authors.lastname: Gottwald
authors.forename: H
authors.initials: H
authors.lastname: Sparwasser
authors.forename: K
authors.initials: K
authors.lastname: Stockamp
authors.forename: W
authors.initials: W
authors.lastname: Aulitzky
authors.forename: J G
authors.initials: JG
authors.lastname: Moormann
authors.forename: K
authors.initials: K
authors.lastname: Schumacher
authors.forename: H
authors.initials: H
authors.lastname: Rasche
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000401:mortality; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives*; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D011379:Prognosis; D011897:Random Allocation; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D007370:Interferon Type I; D011994:Recombinant Proteins; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone